0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover1244.61%IV278.79%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8554Delta0.0574Gamma1.32Leverage Ratio-0.0220Theta0.0001Rho1.13Eff Leverage0.0007Vega
Kronos Bio Stock Discussion
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
Kronos Bio (NASDAQ: KRON) has dosed the first patient in an expansion cohort of its KB-0742 clinical trial, focusing on platinum-resistant high-grade serous ovarian cancer (HGSOC). The trial uses an 80mg dose on a four-days-on, three-days-off schedule, which cleared the dose escalation phase. This dosing regimen is expected to provi...
NEWS
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, t...
• $Cogent Biosciences(COGT.US)$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US)$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US)$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US)$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
No comment yet